| abstract |
The present invention relates to asymmetric fusion proteins in which an antibody fragment that binds to the insulin receptor, an IDS enzyme and an Fc region are fused, and uses thereof. The fusion protein can cross the blood-brain barrier (BBB) to deliver IDS enzymes to the brain. Therefore, the pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for central nervous system diseases, and in particular, it is expected to prevent and treat various diseases caused by accumulation of ribosomes. |